文献速递药物相互作用肝肾功能剂量调整特殊人群用药

达拉非尼的临床药代动力学与药效学

Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

达拉非尼是BRAF突变激酶抑制剂,推荐空腹150 mg每日两次。口服绝对生物利用度95%,因CYP3A4自身诱导,稳态需14天,75-300 mg bid范围内暴露增加低于剂量比例。主要经CYP3A4/2C8氧化代谢和胆汁排泄,羟基达拉非尼有药理活性。轻中度肾或肝损伤无需调整剂量,重度影响未知,存在药物相互作用风险。

要点

  • 达拉非尼推荐空腹150 mg每日两次,口服绝对生物利用度95%。
  • 因CYP3A4自身诱导,稳态需14天,75-300 mg bid暴露增加低于剂量比例。
  • 轻中度肾或肝损伤无需调整剂量,重度损伤影响未知。

核心结论

  • 达拉非尼口服生物利用度高,但因自身诱导CYP3A4,稳态需14天且暴露增加低于剂量比例。
  • 轻中度肾或肝损伤无需调整剂量,重度损伤影响未知。
  • 达拉非尼是CYP3A4/2C8底物和CYP3A4/2B6/2C诱导剂,预期存在药物相互作用。

研究设计与样本

  • 本文为综述,总结达拉非尼的临床药代动力学和药效学特征。

主要发现

  • 单次口服推荐剂量后,达拉非尼绝对口服生物利用度为95%。
  • 多次给药后表观清除率随时间增加,稳态在每日给药14天后达到。
  • 在75-300 mg bid范围内,稳态全身暴露增加低于剂量比例。
  • 年龄、性别和体重对达拉非尼血浆暴露无临床显著影响。

关键数值与推荐

  • 推荐剂量为150 mg每日两次,空腹条件下服用。
  • 轻中度肾或肝损伤无需剂量调整,重度损伤影响未知。

临床怎么用

  • 达拉非尼应空腹服用,150 mg每日两次,注意自身诱导导致稳态延迟。
  • 轻中度肾或肝损伤患者无需调整剂量,重度损伤患者用药需谨慎。
  • 注意CYP3A4/2C8底物和CYP3A4/2B6/2C诱导剂相关的药物相互作用。

局限性

  • 重度肾或肝损伤对达拉非尼药代动力学的影响尚不清楚。
  • 达拉非尼及其活性代谢物羟基达拉非尼血浆暴露与临床结局的关系需深入研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor), for unresectable or metastatic BRAF-mutated melanoma, advanced non-small cell lung cancer and anaplastic thyroid cancer harbouring the BRAFV600E mutation. The recommended dose of dabrafenib is 150 mg twice daily (bid) under fasted conditions. After single oral administration of the recommended dose, the absolute oral bioavailability (F) of dabrafenib is 95%. Dabrafenib shows a time-dependent increase in apparent clearance (CL/F) following multiple doses, which is likely due to induction of its own metabolism through cytochrome P450 (CYP) 3A4. Therefore, steady state is reached only after 14 days of daily dose administration. Moreover, the extent of this auto-induction process is dependent on the dose, which explains why dabrafenib systemic exposure at steady state increases less than dose proportionally over the dose range of 75-300 mg bid. The main elimination route of dabrafenib is the oxidative metabolism via CYP3A4/2C8 and biliary excretion. Among the three major metabolites identified, hydroxy-dabrafenib appears to contribute to the pharmacological activity. Age, sex and body weight did not have any clinically significant influence on plasma exposure to dabrafenib. No dose adjustment is needed for patients with mild renal or hepatic impairment, whereas the impacts of severe impairment on dabrafenib pharmacokinetics remain unknown. Considering that dabrafenib is a substrate of CYP3A4/2C8 and is a CYP3A4/2B6/2C inducer, drug-drug interactions are expected with dabrafenib. The relationship between clinical outcomes and plasma exposure to dabrafenib and hydroxy-dabrafenib should be investigated more deeply.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Puszkiel A, Noé G, Bellesoeur A, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib. Clin Pharmacokinet. 2019. PMID: 30094711. doi:10.1007/s40262-018-0703-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。